Actimis Pharmaceuticals Gets $6M

San Diego-based Actimis Pharmaceuticals said this morning that it has closed a $6M Series A financing round from Sanderling VEntures and Mitsui & Co. The company is a spinout of Bayer HealthCare AG, and is developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases. The company said that Bayer HealthCare Ag has assigned the rights to five preclinical research programs to Actimis. The company's technology is applicable for asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, psoriasis and others. More information »